Physician profile
Anton R Dotson
NPI 1205849858
$8,287.98
in general payments reported to CMS, 2019-2025
31 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $715 · 2021: $1,105 · 2022: $915 · 2023: $1,276 · 2024: $1,374 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,025 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,024.95 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,167.13 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $689.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $599.54 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $500.74 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Amgen INC. | $478.34 | 2021-2025 | Tezspire, Tavneos |
| Pfizer INC. | $288.16 | 2019-2025 | |
| Optinose US, INC. | $284.28 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $255.92 | 2020-2023 | Cuvitru, Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.36 | 2019-2022 | |
| Csl Behring | $214.76 | 2019-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $200.60 | 2019-2025 | |
| Grifols USA, LLC | $200.01 | 2019-2025 | Xembify |
| Mylan Specialty L.P. | $169.11 | 2019-2024 | Yupelri |
| Octapharma USA, INC. | $167.05 | 2019-2024 | Cutaquig |
| Sanofi-Aventis U.S. LLC | $125.61 | 2020-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $109.21 | 2024 | Ayvakit |
| Alk-Abello, INC | $94.09 | 2019-2021 | |
| Shire North American Group INC | $82.49 | 2019 | |
| Genentech USA, INC. | $80.66 | 2019-2023 | Xolair |
| Ionis Pharmaceuticals, INC. | $60.37 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $45.04 | 2019 | |
| Kaleo, INC. | $42.63 | 2022 | |
| Biocryst US Sales Co., LLC | $40.52 | 2021-2022 | |
| Lilly USA, LLC | $37.39 | 2024 | Ebglyss, Taltz |
| Hospira, INC. | $30.45 | 2019-2020 | |
| Greer Laboratories, INC. | $23.31 | 2019 | |
| Viatris Specialty LLC | $19.12 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $17.21 | 2020 | |
| Circassia INC. | $14.79 | 2019 | |
| Galderma Laboratories, L.P. | $13.35 | 2024 | |
| Organon LLC | $6.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Dotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.